オクヤマ　リョウ   OKUYAMA Ryo   奥山 亮    所属   立命館アジア太平洋大学  国際経営学部    職種   教授
言語種別	英語
発行・発表の年月	2023/12
形態種別	学術論文
査読	査読あり
招待論文	招待あり
標題	Academia’s contribution to drug discovery: current status and perspectives in Japan.
執筆形態	単著
掲載誌名	Translational and Regulatory Sciences
掲載区分	国外
巻・号・頁	5(3),pp.57-64
担当区分	筆頭著者,責任著者
著者・共著者	Ryo Okuyama
概要	The international competitiveness of Japan in drug discovery is low. All FDA-approved drugs between 2017-2021 originated by Japanese companies were discovered by long-established pharmaceutical companies. Through the case studies of productive drug discovery ventures and COVID-19 mRNA vaccine development, an established drug discovery ecosystem exists in the west to support the creation of new drugs through researchers’ venture establishment based on promising technologies from academia, attracting substantial investments from investors and large corporations. Conversely, measures to promote university ventures and academic drug discovery have not been effective. From analyzing a productive domestic pharmaceutical company, promoting the alignment between pharma’s new modality technologies and novel drug targets discovered by academia can be effective for advancing drug discovery in Japan. Perspectives for enhancing the competitiveness in drug discovery in Japan is discussed.
DOI	https://doi.org/10.33611/trs.2023-005